WO2001019365A1 - Compositions pharmaceutiques et/ou cosmetiques - Google Patents

Compositions pharmaceutiques et/ou cosmetiques Download PDF

Info

Publication number
WO2001019365A1
WO2001019365A1 PCT/EP2000/008742 EP0008742W WO0119365A1 WO 2001019365 A1 WO2001019365 A1 WO 2001019365A1 EP 0008742 W EP0008742 W EP 0008742W WO 0119365 A1 WO0119365 A1 WO 0119365A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical
acid
composition according
cosmetical
teca
Prior art date
Application number
PCT/EP2000/008742
Other languages
English (en)
Inventor
Raymond De Bony
Eric Gooris
Original Assignee
Roche Consumer Health Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Consumer Health Ag filed Critical Roche Consumer Health Ag
Priority to AU76511/00A priority Critical patent/AU7651100A/en
Publication of WO2001019365A1 publication Critical patent/WO2001019365A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Definitions

  • the present invention relates to pharmaceutical and/or cosmetical compositions for treating dermatological disorders such as wound-healing, chronic venous insufficiency, skin aging, wrinkling, laxity, cellu te and photodamage
  • compositions containing pantothemc acid and/or its de ⁇ vatn es are useful for healing wounds and for treating further dermatological disorders
  • Pantothemc acid which is also known as D(+) lbutyryl) ⁇ - alanine, is a member of the B complex vitamins and is sometimes referred to as vitamin B5
  • Pantothemc acid plays a key role in cellular metabolism, as after incorporation into coenzyme A (CoA), it participates in the synthesis of fatty acids, cholesterol and sterols Through its participation in the Krebs cycle, coenzyme CoA is also instrumental in the generation of energy by the cells Pantothemc acid is hence essential for epithelial regeneration and development in the event of damage to the skin when a high rate of hpids and cellular renewal is needed
  • panthenol the alcohol of the pantothemc acid
  • pantothemc acid has thei efore been used for many years in topical products such as ointments and creams
  • topical products such as ointments and creams
  • the clinical effectiveness of the topical application of in promoting wound healing has been confirmed by several studies in cases of wounds, burns, cracked nipples, ulcers, and bedsores (e.g P.Girard, A Beraud, C Gouion, A Sii ent, J-L Fc atier, B Alleaume, R. de Bony, Les doses Derm todoubtedlys, 17, 1998, pp 559-570)
  • Centella Asiatica is a plant of the umbelhferae family and has been used for wound healing Centella Asiatica is also suitable for cosmetic use such as skin conditioning improvement and anti-celluhte effect Centella Asiatica contains asiatic acid, madecas C acid and asiaticoside, all of which belong to the class of t ⁇ terpenoids Titi ated r or Centella Asiatica (TECA, Serdex) is a combination of 40 wt asiaticoside and 60 wt ° ⁇ > o * the two genines asiatic acid and madecassic acid Titrated Extract of Centella Asiatica is commercially available under the trademark MADECASSOL ® or can be prepared by maceration of dried plants of Centella Asiatica and various purification steps. (International Cosmetic, Ingredient Dictionary, 5th Edition, 1993, Editors: John A. Wenninger et al, published by The Cosmetic, Toiletry, and Fragrance Association).
  • Asiatic acid, asiaticoside and madecassic acid are known and commercially available compounds and can be prepared as described in "International Cosmetic, Ingredient Dictionary", 5th Edition 1993, Editors: John A. Wenninger et al, published by The Cosmetic, Toiletry, and Fragrance Association.
  • compositions comprising from 0.5 to 1.5 wt % of one or more compounds selected from the group consisting of Titrated Extract of Centella Asiatica (TECA), asiaticoside, asiatic acid and madecassic acid, and from 4 to 6 wt % of pantothenic acid and/or its derivatives, show an important activity in the neosynthesis of collagens, in contrast to compositions containing separately the same amount of the two active compounds.
  • TECA Titrated Extract of Centella Asiatica
  • compositions with higher therapeutic activity are therefore obtained without enhancing the amount of active compounds and, therefore, without compromising the patient's tolerance of the active principles and without increasing the manufacturing costs.
  • compositions according to the present invention can contain asiatic acid, asiaticoside and madecassic acid, singly or in any combination thereof.
  • the composition according to the present invention comprises 0.5 to 1.5 wt % of TECA.
  • pantothenic acid any pharmaceutically and/or cosmetically acceptable derivative of pantothenic acid can be used in the compositions of the present invention.
  • examples include alcohols, aldehydes, alcohol esters, acid esters and the like.
  • the preferred derivative of pantothenic acid is pantothenyl alcohol (panthenol), particularly the D(+) of pantothenyl alcohol which is more commonly known as dexpanthenol.
  • pantothenyl triacetate can be chosen.
  • composition according to the present invention may further comprise additional vitamins such as vitamin A, vitamins B other than pantotenic acid, vitamin C and vitamin E.
  • Vitamins B other than pantotenic acid, vitamin C and/or vitamin E can be present in an amount varying from 0.01 wt % to 10.0 wt %, while Vitamin A can be suitably used in concentrations from 1000 to 5000 IU per gram of composition.
  • the composition according to the present invention may contain active principles for this purpose. Examples thereof are escin, rutosides and mixtures thereof. They can be incorporated into the composition either in pure form or by means of natural extracts containing them.
  • a preferred extract containing escin is that of Horse Chestnut, while preferred extracts containing rutosides are those of Sophora Japonica and Gingko Biloba.
  • the composition may also contain minerals for supporting the regeneration and maintenance of human tissues such as the skin and/or the blood vessel tissues.
  • minerals are preferably selected from those including Se, Zn, Mg and Ca.
  • the pharmaceutical and/or cosmetical compositions of the present invention can comprise pharmaceutically and/or cosmetically acceptable additives.
  • Suitable additives are diluents, dispersants and carriers of the active compounds.
  • Additives other than water can include liquid and solid emollients, solvents, thickeners, emulsifiers, preservatives, coloring agents, opacifiers, sunscreens, and the like. The additives form the balance of the composition.
  • Emollients can be chosen from the group consisting of esters, fatty acids and alcohols, polyols, oils and waxes and are preferably present in amounts varying from 0.5 and 60 wt %.
  • Esters may be mono-, di- or triesters such as glyceryloleate, polyethylenglycolstearate, dibutyladipate, diethylsebacate, dioctylsuccinate, triisopropyltrilinoleate or trilaurylcitrate.
  • Esters may also be straight chain fatty acids such as laurylpalmitate, myristyllactate or stearyloleate; or branched chain fatty esters such as isopropylstearate or isostearylpalmitate.
  • Fatty acids and alcohols include those compounds having from 10 to 20 carbon atoms like for example cetyl-, myristyl-, palmitic- and stearyl-alcohols and -acids or lanolin alcohol.
  • Polyols may be linear or branched chain alkyl polyhydroxyl compounds like for example propylene glycol, sorbitol or glycerin or polymeric polyols such as polyethylenglycol (PEG).
  • PEG polyethylenglycol
  • Oils may be mineral oils like paraffin oil or vaseline, vegetable oils like almond oil, palm oil, avocado oil, castor oil or olive oil, silicone oils like for example dimethicone.
  • Waxes may be mineral waxes like paraffin wax, white wax, vaseline or ozokerite or animal waxes like woolfat or beeswax.
  • Solvents are preferably alcohols such as ethanol.
  • Thickeners will usually be present in amounts from 0.1 wt % to 20 wt %.
  • Exemplary thickeners are gelatin or polyacrylamide.
  • Preservatives may include phenoxyethanol, paraben-compounds, chlorphenesin, EDTA, benzylic alcohol, benzalkonium chloride and chlorhexidine.
  • Sunscreens include, in amounts varying from 0.1 wt % to 20 wt %, those materials commonly employed to block ultraviolet light, such as PARSOL® 1789 or PARSOL® MCX.
  • Physical filters such as micronized zinc oxide or titan dioxide, may also be included in the compositions of the present invention.
  • Emulsifiers may be incorporated into the compositions from about 0.1 wt % to 20 wt %.
  • Emulsif ⁇ ers can be nonionic surfactants such as polyalkylene glycol ethers of fatty alcohols, anionic surfactants such as alkyl sulfates, fatty acid soaps, amphoteric surfactants such as dialkylamine oxide.
  • composition according to the present invention is intended primarily as a product for topical application.
  • topical as used in the present specification relates to the use of the above active compounds, which are processed with a suitable carrier material and which is applied to the skin, mucous membrane, hair and/or nails, so that it can display local activity.
  • the topical forms embrace pharmaceutical and/or cosmetical dosage forms which are suitable for external use, so that a direct contact with the skin results.
  • the topical dosage forms embrace gels, creams, lotions, salves, powders, aerosols, emulsions, including oil in water and water in oil, and other conventional forms which are suitable for the direct application of products on the skin or mucous membrane.
  • These dosage forms can be manufactured by mixing the above compounds with known carrier materials which are suitable for topical use.
  • Salves and creams contain oily, absorbent, water-soluble and/or emulsifying carrier materials such as vaseline, paraffin oil, propylene glycol, cetylalcohol, glycerine monostearate, alkyl-branched fatty acids and the like.
  • Lotions are liquid preparations and can vary from simple solutions to aqueous or aqueous/alcoholic preparations which contain the substances in finely divided form.
  • the preparations contain suspended or dispersing substances such as, for example, sodium carboxymethylcellulose which suspend or disperse the active substance in a carrier prepared from water, alcohol, glycerine and the like.
  • Gels are semi-solid preparations which are obtained by gelling a solution or suspension of the active substance in a carrier material.
  • the carrier materials which can be hydrophilic or hydrophobic, are gelled using a gelling agent in form of polymers of biological, natural or synthetical origin.
  • Aerosols are solutions or suspensions of the active substance in a carrier material which are applied using spray generators.
  • carrier material are, for example, trichloromonofluoromethane, trichlorodifluoromethane, volatile silicones, nitrogen, etc..
  • Spays are solutions suspensions or powders of the active substance in a carrier material which are applied using mechanical pumps.
  • compositions according to the present invention are used by applying an amount of the active compounds sufficient to provide a therapeutic and/or cosmetic effect to the skin to be treated.
  • This application can be effected in the usual manner by rubbing, spraying or by a plaster.
  • the topical compositions are usually applied in an amount to provide from 0.1 to 5 mg of active ingredient per cm 2 of the skin per day.
  • the inventive combination can also be administered orally for stimulating collagen synthesis in skin or for the treatment of chronic venous insufficiency and any other diseases originating from collagen deficiency.
  • Oral administrations can be presented, for example, in the form of tablets, capsules, solutions, etc.
  • the compositions of the invention can be administered to adults in amounts of about 10-400 mg/day.
  • the present invention refers also to the use of a combination comprising from 0.5 to 1.5 wt % of one or more compounds selected from the group consisting of Titrated Extract of Centella Asiatica (TECA), asiaticoside, asiatic acid and madecassic acid, and from 4 to 6 wt % of pantothenic acid and/or its derivatives for the manufacture of medicaments and/or cosmetical compositions.
  • TECA Titrated Extract of Centella Asiatica
  • asiaticoside asiatic acid and madecassic acid
  • pantothenic acid and/or its derivatives for the manufacture of medicaments and/or cosmetical compositions.
  • such medicaments and/or cosmetical compositions are used for treating wounds, chronic venous insufficiency, skin aging, wrinkling, laxity, cellulite and photodamage.
  • TECA Titrated Extract of Centella Asiatica
  • PEG 30 dipolyhydroxystearate 4.0g
  • PEG 22 dodecyl glycol copolymer 3.0g
  • Microcrystalline wax 2.0g
  • Purified water up to 100 g
  • the above composition was applied to male and female human volunteers between 20 and 45 years on wounds created according to an artificial wound model (biopsies with a 3 mm punch).
  • the wound healing degree was evaluated after 1, 3, 6 and 10 days of treatment, with a scoring of epidermisation and dermis restructuring made on Dermascan echographies.
  • the evaluation of the wound status was carried out by means of video microscopic images taken at different times during the healing period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques et/ou cosmétiques contenant entre 0,5 et 1,5 % en poids d'un ou plusieurs composés sélectionnés dans le groupe comprenant un extrait titré de Centella Asiatica (TECA), d'asiaticoside, d'acide asiatique et d'acide madecassique, et entre 4 et 6 % en poids d'acide pantothénique et/ou de ses dérivés. Les compositions de cette invention présentent une activité importante dans la néosynthèse des collagènes, par rapport aux compositions contenant séparément la même quantité des deux composés acides. Ces compositions sont appropriées pour traiter des affections dermatologiques telles que la cicatrisation des plaies, l'insuffisance veineuse chronique, le vieillissement de la peau, les rides, la laxité de la peau, la cellulite et les lésions dues à l'action de la lumière sur la peau.
PCT/EP2000/008742 1999-09-15 2000-09-07 Compositions pharmaceutiques et/ou cosmetiques WO2001019365A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76511/00A AU7651100A (en) 1999-09-15 2000-09-07 Pharmaceutical and/or cosmetical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99118284 1999-09-15
EP99118284.1 1999-09-15

Publications (1)

Publication Number Publication Date
WO2001019365A1 true WO2001019365A1 (fr) 2001-03-22

Family

ID=8239004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008742 WO2001019365A1 (fr) 1999-09-15 2000-09-07 Compositions pharmaceutiques et/ou cosmetiques

Country Status (3)

Country Link
AR (1) AR025657A1 (fr)
AU (1) AU7651100A (fr)
WO (1) WO2001019365A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080880A2 (fr) * 2002-05-02 2002-10-17 Priscilla S.R.L. Unipersonale Preparation anti-vergetures et procede associe
WO2002096447A2 (fr) * 2001-05-30 2002-12-05 Weber & Weber Gmbh & Co. Kg Preparation pharmaceutique
ES2199072A1 (es) * 2002-07-19 2004-02-01 Aumas Retrotenn Estetica S L Regenerante epitelial
FR2848117A1 (fr) * 2002-12-10 2004-06-11 Roche Consumer Health Ltd Procede de preparation d'un extrait de centella asiatica riche en madecassoside et en terminoloside
WO2008142619A1 (fr) * 2007-05-17 2008-11-27 Izun Pharmaceuticals Corporation Utilisation de compositions à base de plantes dans la protection et l'amplification des composants de la matrice extracellulaire
WO2009071213A1 (fr) * 2007-12-06 2009-06-11 Bayer Consumer Care Ag Propriétés anti-glycation de l'acide asiatique et de l'acide madécassique
DE102009047092A1 (de) * 2009-11-24 2011-05-26 Birken Gmbh Verwendung eines triterpenhaltigen Oleogels zur Wundheilung
US20110262563A1 (en) * 2008-07-25 2011-10-27 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US8071137B2 (en) 2005-09-27 2011-12-06 Advanced Technologies And Regenerative Medicine, Llc Method for treatment of cartilage disorders with centella extract
WO2014158685A3 (fr) * 2013-03-14 2015-10-29 Avon Products, Inc Extraits de tetracera asiatica et procédés d'utilisation
KR20160011964A (ko) * 2014-07-23 2016-02-02 주식회사 엘지생활건강 피부 외용제 조성물
US9572810B2 (en) 2010-07-22 2017-02-21 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US11083733B2 (en) 2018-01-04 2021-08-10 Amryt Research Limited Betulin-containing birch bark extracts and their formulation
CN113230172A (zh) * 2021-05-24 2021-08-10 泉州达浔生物科技有限公司 一种化妆品或皮肤病学组合物及其制备方法和应用
US11494000B2 (en) 2011-09-19 2022-11-08 Eyesight Mobile Technologies Ltd. Touch free interface for augmented reality systems

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668061A1 (fr) * 1990-10-19 1992-04-24 Thorel Jean Noel Compositions cosmetiques pour le contour des yeux.
WO1997003676A1 (fr) * 1995-07-21 1997-02-06 Cabo Soler Jose Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee
EP0852946A2 (fr) * 1996-11-29 1998-07-15 Gianfranco De Paoli Ambrosi Composition cosmétique, pharmaceutique et/ou diététique à base d'un sucre aminé et/ou d'acide polyhydroxylique
FR2770776A1 (fr) * 1997-11-07 1999-05-14 Lvmh Rech Utilisations du d-xylose et de ses esters pour ameliorer la fonctionnalite des cellules de l'epiderme
US5945109A (en) * 1996-03-29 1999-08-31 S.W. Patentverwertungs Ges.M.B.H. Cosmetic or cosmetic product for firming and smoothing the skin, in particular in the case of cellulite

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668061A1 (fr) * 1990-10-19 1992-04-24 Thorel Jean Noel Compositions cosmetiques pour le contour des yeux.
WO1997003676A1 (fr) * 1995-07-21 1997-02-06 Cabo Soler Jose Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee
US5945109A (en) * 1996-03-29 1999-08-31 S.W. Patentverwertungs Ges.M.B.H. Cosmetic or cosmetic product for firming and smoothing the skin, in particular in the case of cellulite
EP0852946A2 (fr) * 1996-11-29 1998-07-15 Gianfranco De Paoli Ambrosi Composition cosmétique, pharmaceutique et/ou diététique à base d'un sucre aminé et/ou d'acide polyhydroxylique
FR2770776A1 (fr) * 1997-11-07 1999-05-14 Lvmh Rech Utilisations du d-xylose et de ses esters pour ameliorer la fonctionnalite des cellules de l'epiderme

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096447A2 (fr) * 2001-05-30 2002-12-05 Weber & Weber Gmbh & Co. Kg Preparation pharmaceutique
WO2002096447A3 (fr) * 2001-05-30 2003-03-13 Weber & Weber Gmbh & Co Kg Preparation pharmaceutique
WO2002080880A2 (fr) * 2002-05-02 2002-10-17 Priscilla S.R.L. Unipersonale Preparation anti-vergetures et procede associe
WO2002080880A3 (fr) * 2002-05-02 2004-02-26 Priscilla S R L Unipersonale Preparation anti-vergetures et procede associe
ES2199072A1 (es) * 2002-07-19 2004-02-01 Aumas Retrotenn Estetica S L Regenerante epitelial
WO2004062678A1 (fr) * 2002-12-10 2004-07-29 Bayer Consumer Care Ag Procede de preparation d’un extrait de centella asiatica riche en madecassoside et en terminoloside
US8163706B2 (en) 2002-12-10 2012-04-24 Bayer Consumer Care Ag Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside
US7402669B2 (en) 2002-12-10 2008-07-22 Bayer Consumer Care Ag Method for preparing a Centella asiatica extract rich in madecassoside and in terminoloside
FR2848117A1 (fr) * 2002-12-10 2004-06-11 Roche Consumer Health Ltd Procede de preparation d'un extrait de centella asiatica riche en madecassoside et en terminoloside
US8486900B2 (en) 2002-12-10 2013-07-16 Bayer Consumer Care Ag Method for preparing a Centella asiatica extract rich in madecassoside and in terminoloside
US8071137B2 (en) 2005-09-27 2011-12-06 Advanced Technologies And Regenerative Medicine, Llc Method for treatment of cartilage disorders with centella extract
WO2008142619A1 (fr) * 2007-05-17 2008-11-27 Izun Pharmaceuticals Corporation Utilisation de compositions à base de plantes dans la protection et l'amplification des composants de la matrice extracellulaire
WO2009071213A1 (fr) * 2007-12-06 2009-06-11 Bayer Consumer Care Ag Propriétés anti-glycation de l'acide asiatique et de l'acide madécassique
US9089511B2 (en) 2008-07-25 2015-07-28 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US9775798B2 (en) 2008-07-25 2017-10-03 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US20110262563A1 (en) * 2008-07-25 2011-10-27 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US11110053B2 (en) 2008-07-25 2021-09-07 Reven Pharmaceuticals Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US9089602B2 (en) 2008-07-25 2015-07-28 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US9827214B2 (en) 2009-11-24 2017-11-28 Amryt Research Limited Use of an oleogel containing triterpene for healing wounds
DE102009047092A1 (de) * 2009-11-24 2011-05-26 Birken Gmbh Verwendung eines triterpenhaltigen Oleogels zur Wundheilung
US9352041B2 (en) 2009-11-24 2016-05-31 Birken Ag Use of an oleogel containing triterpene for healing wounds
JP2013511568A (ja) * 2009-11-24 2013-04-04 ビルケン アーゲー 創傷を治癒するためのトリテルペン含有オレオゲルの使用
US9572810B2 (en) 2010-07-22 2017-02-21 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US9867849B2 (en) 2010-07-22 2018-01-16 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US11202798B2 (en) 2010-07-22 2021-12-21 Reven Pharmaceuticals, Inc. Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US11494000B2 (en) 2011-09-19 2022-11-08 Eyesight Mobile Technologies Ltd. Touch free interface for augmented reality systems
WO2014158685A3 (fr) * 2013-03-14 2015-10-29 Avon Products, Inc Extraits de tetracera asiatica et procédés d'utilisation
KR102274295B1 (ko) * 2014-07-23 2021-07-07 주식회사 엘지생활건강 피부 외용제 조성물
KR20160011964A (ko) * 2014-07-23 2016-02-02 주식회사 엘지생활건강 피부 외용제 조성물
US11083733B2 (en) 2018-01-04 2021-08-10 Amryt Research Limited Betulin-containing birch bark extracts and their formulation
US11266660B2 (en) 2018-01-04 2022-03-08 Amryt Research Limited Betulin-containing birch bark extracts and their formulation
US11826374B2 (en) 2018-01-04 2023-11-28 Amryt Research Limited Betulin-containing birch bark extracts and their formulation
CN113230172A (zh) * 2021-05-24 2021-08-10 泉州达浔生物科技有限公司 一种化妆品或皮肤病学组合物及其制备方法和应用
CN113230172B (zh) * 2021-05-24 2022-07-01 泉州达浔生物科技有限公司 一种化妆品或皮肤病学组合物及其制备方法和应用

Also Published As

Publication number Publication date
AR025657A1 (es) 2002-12-11
AU7651100A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
US11571373B2 (en) Skin care preparations for babies
RU2320362C2 (ru) Местные фармацевтические композиции, содержащие проантоцианидины, для лечения дерматитов
WO2020024703A1 (fr) Composition topique de fullerène soluble dans l'eau
AU2002317053B2 (en) Dermal therapy using phosphate derivatives of electron transfer agents
KR20040012913A (ko) 양파 추출물을 함유하는 지방(오일) 함유 약품, 이의 생산및 손상된 피부 조직, 특히 흉터 조직을 관리, 예방 또는치료하기 위한 이의 용도
JP2008526963A (ja) 過度に色素沈着した皮膚を処置するための組成物および方法
WO2001019365A1 (fr) Compositions pharmaceutiques et/ou cosmetiques
CN108186679B (zh) 一种祛痘组合物
JPH027287B2 (fr)
JPH08245409A (ja) 皮膚外用剤及び浴用剤
KR101418366B1 (ko) 봉독 및 프로폴리스를 함유하는 여드름 예방 또는 치료용 조성물
JP2007084448A (ja) ヒアルロン酸産生促進剤および皮膚外用剤
JPH06305932A (ja) 皮膚外用剤
JPH11139951A (ja) 化粧料
EP0613368A1 (fr) Composition cosmetique de regeneration cutanee.
JP4934280B2 (ja) シワ改善剤
WO2001045697A1 (fr) Agents et medicaments a usage cutane externe
KR101322850B1 (ko) 박하잎 추출물, 밀싹 추출물 및 길경 추출물을 유효성분으로 포함하는 모공 축소 또는 피지분비 억제용 화장료 조성물
WO2004110396A1 (fr) Agents topiques contenant de l'acide phytanique ou un derive de ce dernier
JP2000007548A (ja) 皮膚外用剤
JP2003238429A (ja) 線維芽細胞賦活剤及びこれを含む皮膚外用剤
JPH11255661A (ja) アトピー性皮膚炎用外用剤
JP4950390B2 (ja) 皮膚外用剤
KR100292143B1 (ko) 글리콜산과 비타민c를 함유하는 화장용 조성물
JP5313524B2 (ja) 抗炎症剤及び抗炎症用皮膚外用剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP